EP1161255A4 - Verfahren und mittel zur behandlung erektiler dysfunktion - Google Patents

Verfahren und mittel zur behandlung erektiler dysfunktion

Info

Publication number
EP1161255A4
EP1161255A4 EP00916081A EP00916081A EP1161255A4 EP 1161255 A4 EP1161255 A4 EP 1161255A4 EP 00916081 A EP00916081 A EP 00916081A EP 00916081 A EP00916081 A EP 00916081A EP 1161255 A4 EP1161255 A4 EP 1161255A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
erectile dysfunction
treating erectile
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00916081A
Other languages
English (en)
French (fr)
Other versions
EP1161255A2 (de
Inventor
Elizabeth Stoner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP1161255A2 publication Critical patent/EP1161255A2/de
Publication of EP1161255A4 publication Critical patent/EP1161255A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
EP00916081A 1999-03-08 2000-03-03 Verfahren und mittel zur behandlung erektiler dysfunktion Withdrawn EP1161255A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12324499P 1999-03-08 1999-03-08
US123244P 1999-03-08
PCT/US2000/005711 WO2000053148A2 (en) 1999-03-08 2000-03-03 Methods and compositions for treating erectile dysfunction

Publications (2)

Publication Number Publication Date
EP1161255A2 EP1161255A2 (de) 2001-12-12
EP1161255A4 true EP1161255A4 (de) 2002-07-17

Family

ID=22407530

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00916081A Withdrawn EP1161255A4 (de) 1999-03-08 2000-03-03 Verfahren und mittel zur behandlung erektiler dysfunktion

Country Status (4)

Country Link
EP (1) EP1161255A4 (de)
AU (1) AU3724400A (de)
CA (1) CA2362918A1 (de)
WO (1) WO2000053148A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6943166B1 (en) 1999-04-30 2005-09-13 Lilly Icos Llc. Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
HUP0001632A3 (en) * 1999-04-30 2001-12-28 Lilly Icos Llc Wilmington Pharmaceutical compositions comprising selective phosphodiestherase inhibitors
US7235625B2 (en) 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
US7176279B2 (en) 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
EP2338491A3 (de) 1999-08-03 2011-11-30 Lilly ICOS LLC Pharmazeutische Zusammensetzung enthaltend ein Beta-Carbolin
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
AU2002238106A1 (en) 2001-02-13 2002-08-28 Palatin Technologies, Inc. Melanocortin metallopeptides for treatment of sexual dysfunction
CA2453609C (en) * 2001-07-18 2010-05-04 Merck & Co., Inc. Bridged piperidine derivatives as melanocortin receptor agonists
BR0305628A (pt) 2002-07-09 2004-09-08 Palatin Technologies Inc Composição farmacêutica para tratar disfunção sexual num mamìfero compreendendo peptìdeo e seu uso

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962528A (en) * 1991-07-03 1999-10-05 Scott; Nathan Earl Prostaglandin E2 /F2α combination for treating impotence
ATE190843T1 (de) * 1993-02-10 2000-04-15 Bmra Corp Bv Zubereitungen zur behandlung von impotenz, die ein alpha-1 inhibitor und ein alpha-2 inhibitor enthalten
EP0696919B1 (de) * 1993-04-05 2002-01-30 Competitive Technologies, Inc. Diagnose und behandlung von erektilen funktionsstörungen
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB9423911D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
US5731339A (en) * 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
US5994294A (en) * 1996-02-02 1999-11-30 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US5932538A (en) * 1996-02-02 1999-08-03 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
CN1282248A (zh) * 1997-12-16 2001-01-31 辉瑞产品公司 阳萎的联合治疗
AU1827299A (en) * 1997-12-18 1999-07-05 Nathan Earl Scott Prostaglandin e2/f2alpha combination for treating impotence and enhancing sexual arousal
GT199900061A (es) * 1998-05-15 2000-10-14 Pfizer Formulaciones farmaceuticas.
AU4068599A (en) * 1998-05-20 1999-12-06 Schering Corporation Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction
US6124461A (en) * 1998-05-26 2000-09-26 Saint Louis University, Health Services Center, Research Administration Compounds, compositions, and methods for treating erectile dysfunction
US6200591B1 (en) * 1998-06-25 2001-03-13 Anwar A. Hussain Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction
US6007824A (en) * 1998-07-09 1999-12-28 Duckett; Melvin J. Natural composition and method for the treatment of sexual dysfunction

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HEDLUND-H ET AL.: "Pharmacotherapy in erectile dysfunction agents for self-injection programs and alternative application methods", SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, vol. 179, no. Suppl, 1996, pages 129 - 138, XP001064596 *
HUNTER WESSELS ET AL.: "Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study", THE JOURNAL OF UROLOGY, vol. 160, 1998, pages 389 - 393, XP001064550 *
See also references of WO0053148A3 *

Also Published As

Publication number Publication date
AU3724400A (en) 2000-09-28
EP1161255A2 (de) 2001-12-12
CA2362918A1 (en) 2000-09-14
WO2000053148A3 (en) 2000-12-14
WO2000053148A2 (en) 2000-09-14

Similar Documents

Publication Publication Date Title
EP1005336A4 (de) Verbesserte verfahren und zusammensetzungen zur behandlung männlicher erektionsstörungen
HUP0103346A3 (en) Composition and method for treating penile erectile dysfunction
HUP0201436A3 (en) Methods and compositions for treating solid tumors
EP1164848A4 (de) ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERMEIDUNG UND BEHANDLUNG SEXUELLER FUNKTIONSSTöRUNGEN
AP2006003708A0 (en) Methods and compositions for treating flavivirusesand pestiviruses
EP1143987A4 (de) Natürliche zusammensetzung und methode zur behandlung von sexuellen dysfunktionen
AU4768301A (en) Synergistic methods and compositions for treating cancer
EP1229934A4 (de) Zusammensetzungen und verfahren zur behandlung von krebs mittels immunkonjugaten und chemotherapeutischen agenzien
GB9608408D0 (en) Treatment of erectile dysfunction
AU6147401A (en) Compositions and methods for the treatment of cancer
HK1061669A1 (en) Processes and compositions for water treatment
AU4314199A (en) Compounds, compositions and methods for treating erectile dysfunction
IL144517A0 (en) Compositions and methods for treating cataracts
GB9920678D0 (en) Sanitising compositions and methods
AU2001250821A1 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
IL146764A0 (en) Method and composition for masking mineral taste
EP1161255A4 (de) Verfahren und mittel zur behandlung erektiler dysfunktion
HU0001629D0 (en) Method for treating plants and compositions for it
HUP0103206A3 (en) A device and method for the treatment of erectile dysfunction and for its making
EP1677754A4 (de) Verfahren und zusammensetzungen zur behandlung der erektilen dysfunktion
AU3048501A (en) An improved pharmaceutical composition for treating male erectile dysfunction
EP1223957A4 (de) Methode zur behandlung erektiler dysfunktion
IL149200A0 (en) Peptides for treatment of erectile dysfunction
EP1261331A4 (de) Methoden und zusammenstellungen zur behandlung von fibrotischen erkrankungen
EP1157694A4 (de) Heilmittel der erektionsstörung

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011008

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20011008;LT PAYMENT 20011008;LV PAYMENT 20011008;MK PAYMENT 20011008;RO PAYMENT 20011008;SI PAYMENT 20011008

A4 Supplementary search report drawn up and despatched

Effective date: 20020531

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 38/08 A, 7A 61K 31/415 B, 7A 61K 31/505 B, 7A 61K 38/12 B, 7A 61P 15/10 B, 7A 61K 38/12 J, 7A 61K 31:00 J

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020823